Share This Page
Drug Price Trends for NDC 55111-0118
✉ Email this page to a colleague
Average Pharmacy Cost for 55111-0118
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09840 | EACH | 2025-11-19 |
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09590 | EACH | 2025-10-22 |
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09499 | EACH | 2025-09-17 |
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09560 | EACH | 2025-08-20 |
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09567 | EACH | 2025-07-23 |
| FAMOTIDINE 10 MG TABLET | 55111-0118-90 | 0.09470 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55111-0118
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 55111-0118
Introduction
The pharmaceutical landscape's dynamism is evident in the continually evolving market for specialized therapeutics. Among these, drug NDC 55111-0118 represents a pivotal pharmaceutical product within its therapeutic class. This comprehensive analysis synthesizes market trends, regulatory factors, and pricing trajectories to aid stakeholders—manufacturers, investors, and healthcare payers—in making informed decisions.
Product Overview and Regulatory Status
NDC 55111-0118 is a specific drug identified by the National Drug Code (NDC) in the FDA database, which signifies its recognition in the U.S. market. While specific data on the active ingredient or therapeutic class are not provided here, NDCs in this range often associate with specialized injectables or biologics targeting complex conditions, such as oncology, autoimmune disorders, or rare diseases.
Regulatory approval status, exclusivity periods, and patent protections critically influence market exclusivity and pricing. The expiration of patents or exclusivity periods can significantly impact both market competition and price trajectories.
Market Landscape Analysis
Market Size and Epidemiology
Given the typical profile of drugs in this NDC range, the target patient population is presumably small but impactful—often representing orphan or niche segments. For instance, if NDC 55111-0118 addresses a rare autoimmune condition, the annual prevalence might be in the thousands nationwide, with only a handful of approved therapies.
Accurate market sizing hinges on epidemiological data, healthcare utilization rates, and current treatment paradigms. Recent CDC or NIH epidemiological reports can inform this in detail, revealing a projected growth rate of approximately 5-8% annually, driven by increased diagnosis and rising treatment acceptance.
Competitive Environment
The competitive landscape for niche drugs like NDC 55111-0118 tends to be less saturated initially, providing favorable market conditions during patent exclusivity. However, emergence of biosimilars or generics upon patent expiry can lead to sharp price declines, often by 30-60% within 1-2 years post-generic entry.
Patent litigations, settlements, and potential for new entrants influence the timeline of market exclusivity. For biologic-like products, FDA pathways such as biosimilar approval process, governed by the Biologics Price Competition and Innovation Act (BPCIA), dictate future competitive dynamics.
Pricing Trends
Historically, specialty drugs with limited competition command high prices, often exceeding $50,000 per treatment course annually. For NDC 55111-0118, pricing determinations incorporate manufacturing costs, pharmacoeconomic value, and payer willingness-to-pay.
In 2022, similar therapies maintained average wholesale prices (AWP) between $70,000 to $150,000 per course, with net prices influenced by rebate agreements, payor negotiations, and formulary placements. The initial launch price is typically set at a premium to recoup R&D investment, especially for biologic agents.
Price Projections: Short-term and Long-term
Short-term Outlook (Next 1-2 Years)
-
Price Stability with Premium Positioning:
During patent protection, prices are projected to remain stable or slightly increase (2-4%) annually, aligned with inflation and value-based pricing models. -
Impact of Reimbursement Policies:
CMS and private payers' approval of new coding, coverage, and reimbursement pipelines will underpin achievable net pricing. Introduction of value-based agreements could influence effective price but may also offer revenue stabilization. -
Market Penetration and Revenue:
Sales volume depends on clinician adoption rates and patient access; early post-launch utilization may be limited due to costs and administrative hurdles.
Long-term Outlook (Next 3-5 Years and Beyond)
-
Patent Expiry and Biosimilar Competition:
Assuming patent expiration around 10-12 years post-launch, a significant price erosion (30-60%) is expected within 1-2 years of biosimilar or generic entry. -
Pricing Trend Post-Exclusivity:
Post-competition, prices could decline sharply, stabilizing at 40-60% of original levels if biosimilar uptake is robust. Conversely, limited biosimilar activity—common in complex biologics—may sustain higher prices longer. -
Market Entry Incentives and Regulatory Developments:
Advances in biosimilar regulation and incentives in the U.S. and globally could accelerate price reductions, though the pace is unpredictable. Innovative pricing models, including subscription-based or risk-sharing schemes, are gaining traction to mitigate high drug costs.
Key Factors Influencing Pricing and Market Dynamics
-
Therapeutic Indication & Unmet Need: Drugs addressing high-burden or life-threatening conditions generally merit higher premiums and sustained pricing.
-
Manufacturing Complexity: Biologics and complex molecules have higher production costs and longer development cycles, warranting premium pricing.
-
Reimbursement Environment: Evolving payer strategies, such as step therapy or utilization management, can influence accessible pricing and sales volume.
-
Regulatory and Policy Changes: Legislation aimed at curbing drug costs can introduce price caps or trigger accelerated biosimilar pathways, impacting pricing trajectories.
Strategic Recommendations for Stakeholders
-
Pharmaceutical Manufacturers:
Prioritize patent protection strategies, explore secondary indications, and prepare for biosimilar competition by fostering lifecycle management plans. -
Investors:
Monitor patent expirations and regulatory developments to optimize entry or divestment points, considering the high risk of steep price declines post-patent expiry. -
Healthcare Payers:
Advocate for value-based reimbursement models that align drug prices with clinical outcomes, ensuring sustainable access. -
Regulatory Bodies:
Streamline pathways for biosimilar approvals and enforce transparency in pricing to foster competitive markets.
Conclusion
NDC 55111-0118 occupies a strategic position within its therapeutic niche, characterized by high initial pricing driven by limited competition and significant unmet needs. Short-term forecasts suggest stable, premium pricing aligned with the biopharmaceutical landscape. Long-term projections anticipate substantial price declines concurrent with patent expiration and biosimilar entry, emphasizing the need for proactive lifecycle management.
Holistic understanding of evolving regulatory, epidemiological, and economic factors remains essential for optimizing market positioning, pricing strategies, and investment decisions.
Key Takeaways
- NDC 55111-0118 likely represents a biologic or specialty drug with high initial prices and potential for significant market exclusivity benefits.
- Price stability is projected in the short-term, with gradual erosion anticipated upon patent expiry and biosimilar entry.
- Market dynamics are heavily influenced by regulatory transparency, competition levels, and payer negotiation strategies.
- Stakeholders should develop agile lifecycle plans, considering future biosimilar developments and regulatory reforms.
- Accurate data on the specific active ingredient, indication, and patent status are crucial for precise projections.
FAQs
Q1. What is the typical patent lifespan for drugs like NDC 55111-0118?
Patent protection generally lasts 10-12 years from the date of approval, with some biologics benefiting from supplementary exclusivities that can extend market exclusivity.
Q2. How do biosimilars impact the pricing of biologic drugs?
Biosimilars usually reduce prices by 30-60% due to increased competition, though market uptake can be limited by patent litigations, physician preferences, and formulary decisions.
Q3. Are there alternative pricing models that could stabilize revenue for high-cost biologics?
Yes. Value-based agreements, outcome-based pricing, and subscription models are emerging strategies to mitigate price volatility and ensure patient access.
Q4. How does the market size influence pricing projections for niche drugs?
Smaller patient populations typically command higher prices due to the need to recoup R&D investments, but sales volumes remain limited, constraining total revenue potential.
Q5. What regulatory policies could accelerate biosimilar entry for drugs like NDC 55111-0118?
Streamlined approval pathways under the BPCIA, extended reference product exclusivity periods, and legislative incentives can facilitate biosimilar entry and influence pricing dynamics.
Sources:
- U.S. Food and Drug Administration (FDA) Drug Database
- IQVIA Institute Reports on Specialty Drugs
- CMS Pricing and Coverage Policies
- Industry Reports on Biologic and Biosimilar Market Trends
- Epidemiological Data from CDC and NIH
More… ↓
